Developmental outcome of the use of etamsylate for prevention of periventricular haemorrhage in a randomised controlled trial

Schulte, JaneF; Osborne, J P; Benson, J. W. T.; Cooke, R W; Drayton, M.R.; Murphy, J. D.; Rennie, J; Speidel, B D

doi:10.1136/adc.2003.035790

Cited by 28 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second trial, in which 334 premature infants received ethamsylate in the first 4 h after birth, showed no difference in incidence of IVH compared with placebo group. In both trials, long-term patient follow-up showed no benefits in neurodevelopmental outcomes and neuromotor or cognitive function (Elbourne et al, 2001;Schulte et al, 2005). Failure of indomethacin and ethamsylate to improve the IVH global outcome is probably attributable to the fact that although COX inhibition may prevent the initial increase in CBF causing IVH, it could lead to harmful neuronal effects.…”

Section: Prostacyclin Metabolism and Cerebral Intraventricular Hemmentioning

confidence: 99%

Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn

2012

View full text Add to dashboard Cite

Section: Prostacyclin Metabolism and Cerebral Intraventricular Hemmentioning

confidence: 99%

Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn

2012

View full text Add to dashboard Cite

“…Thus, the main effect of etamsylate falls on intact platelets, thereby potentially increasing the risk of blood clot formation, on the one hand, and remaining ineffective during non-capillary bleeding, on the other. [26][27][28][29] It should be noted that the Compound I did not cause spontaneous aggregation. This fact suggests that at the moment of induced aggregation the Compound I has a more selective effect on activated platelets and increases the overall hemostatic potential.…”

Section: Discussionmentioning

confidence: 97%

Hemostatical activity of new benzylammonium salt, 2-[3-methyl-1-npropyl-7-(1,1-dioxotiethanyl-3)xantinyl-8-thio]acetic acid

Ураков¹,

Самородов²,

Камилов³

et al. 2017

Natl J Physiol Pharm Pharmacol

View full text Add to dashboard Cite

Background: Preventing and control of bleeding is important in various areas of clinical medicine in the light of increasing number of patients with hemorrhagic manifestations, extensive use of anticoagulants, increasing number of invasive diagnostic, and treatment methods. However, the drugs traditionally used in medical practice to control bleeding are often inefficient and unable to lead to effective reduction in blood loss. One of the ways to find new methods of bleeding prophylaxis is to develop means of pharmacological correction of hemostasis system. The results of the previous research show potentially high activity of some new nitrogen-containing heterocyclic derivatives relating to hemostasis system in vitro and in vivo. Aims and Objectives: To examine system hemostatic activity of first synthesized benzylammonium salt 2-[3-methyl-1-npropyl-7-(1,1-dioxothietanil-3) xantinyl-8-thio]acetic acid (Compound I) under experimental conditions in vitro and in vivo. Materials and Methods: Experimental work in vitro is performed on the blood of healthy male donors, under conditions in vivo it is done on intraperitoneal injection of equimolar concentrations of the test substances. Thromboelastography (TEG) was carried out with apparatus TEG 5000. The analysis of the thromboelastograms enabled to define general tendency of coagulation, functional activity of platelets and fibrinogen, fibrinolysis activity, and physicomechanical properties of the formed clots. The influence of firstly synthesized xanthine derivative and ethamsylate on the functional activity of platelets in vitro and in vivo was studied using a laser platelet aggregation analyzer "Biola 230LA." The research evaluated the general nature of aggregation, value of maximum aggregation, maximum rate of aggregation, and average size of platelet aggregates. Experimental evaluation of the system specific hemostatic activity in vivo was carried out using the model of parenchymatous bleeding in immature male rats. Results: The interference came amid registration of bleeding stop time and extent of blood loss. Proagregate effect of Compound I is successfully realized into the system hemostatic activity under conditions of parenchymatous bleeding, exceeding the performance of the control group and the etamsylate group. Conclusion: The findings reveal potentially high systemic hemostatic activity of Compound I, convincing of the need to further study this compound and its analogues to create on their basis highly efficient, selective correctors of hemostasis system.

show abstract

“…Ethamsylate (now renamed etamsylate) was first shown in 1981 to reduce IVH in a group of premature babies, 5 and recently a report on the outcome of survivors at the age of 3.5-4.2 years of a large multicentre trial 6 has been published. There was no reduction in the rate of either cerebral palsy or intellectual impairment when the two groups were compared.…”

Section: Etamsylatementioning

confidence: 99%

Minimising neonatal brain injury: how research in the past five years has changed my clinical practice

Levene

2007

Archives of Disease in Childhood

View full text Add to dashboard Cite

Developmental outcome of the use of etamsylate for prevention of periventricular haemorrhage in a randomised controlled trial

Cited by 28 publications

References 17 publications

Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn

Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn

Hemostatical activity of new benzylammonium salt, 2-[3-methyl-1-npropyl-7-(1,1-dioxotiethanyl-3)xantinyl-8-thio]acetic acid

Minimising neonatal brain injury: how research in the past five years has changed my clinical practice

Contact Info

Product

Resources

About